Ethyl 5-(3-chlorophenyl)-1,4-dimethylpyrazole-3-carboxylate | 1428229-03-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Ethyl 5-(3-chlorophenyl)-1,4-dimethylpyrazole-3-carboxylate
• 英文别名: ethyl 5-(3-chlorophenyl)-1,4-dimethylpyrazole-3-carboxylate
• CAS: 1428229-03-1
• 化学式: C₁₄H₁₅ClN₂O₂
• 分子量: 278.738
• InChiKey: SRIYZISFZLDJMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Ethyl 5-(3-chlorophenyl)-1,4-dimethylpyrazole-3-carboxylate 在 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成
  参考文献：
  名称：

  Fragment-Based Lead Generation of 5-Phenyl-1H-pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors

  摘要：

  FXIa被认为是抗凝药物发现的主要靶点，因为减少了出血风险。在这篇论文中，我们将5-苯基-1H-吡唑-3-羧酸衍生物定义为FXIa抑制剂的引物片段，用于引物发现。在将化合物3中的(E)-3-(5-氯-2-(1H-四唑-1-基)苯基)丙烯酰胺基团替换为5-(3-氯苯基)-1H-吡唑-3-羧酰胺后，我们从FXIa抑制剂3转变为将引物片段融合成FXIa抑制剂的药效团的支架。随后，我们合成并评估了一系列具有不同P1、P1'和P2'基团的5-苯基-1H-吡唑-3-羧酰胺衍生物的FXIa抑制活性。最后，对它们的结构活性关系进行了系统研究，得到了引物化合物7za（FXIa Ki = 90.37 nM，在兔血浆中1.5× aPTT = 43.33μM），该化合物表现出良好的体外抑制FXIa活性和优秀的体外凝血活性。此外，研究了7za与FXIa的结合方式，结果表明7za的2-甲基环丙烷甲酰胺基团与FXIa骨架中的Tyr58B和Thr35直接形成两个氢键，使7za以高效的方式结合到FXIa上。

  DOI：

  10.3390/molecules23082002
• 作为产物：
  描述：

  3'-氯丙酮苯 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 生成 Ethyl 5-(3-chlorophenyl)-1,4-dimethylpyrazole-3-carboxylate
  参考文献：
  名称：

  Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators

  摘要：

  Development of SAR in a 5-aryl-3-acylpyridinyl-pyrazoles and 1-aryl-4-acylpyridinyl imidazoles series of mGlu5 receptor negative allosteric modulators (mGluR5 NAMs) using a functional cell-based assay is described in this Letter. Analysis of the Ligand-lipophilic efficiency (LipE) of compounds provided new insight for the design of potent mGluR5 negative allosteric modulators with anti-depressant activities. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.116

文献信息

• Fragment-Based Lead Generation of 5-Phenyl-1H-pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors
  作者：Qunchao Wei、Zhichao Zheng、Shijun Zhang、Xuemin Zheng、Fancui Meng、Jing Yuan、Yongnan Xu、Changjiang Huang

  DOI：10.3390/molecules23082002

  日期：——

  FXIa is suggested as a major target for anticoagulant drug discovery because of reduced risk of bleeding. In this paper, we defined 5-phenyl-1H-pyrazole-3-carboxylic acid derivatives as privileged fragments for FXIa inhibitors’ lead discovery. After replacing the (E)-3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)acrylamide moiety in compound 3 with 5-(3-chlorophenyl)-1H-pyrazole-3-carboxamide, we traveled from FXIa inhibitor3 to a scaffold that fused the privileged fragments into a pharmacophore for FXIa inhibitors. Subsequently, we synthesized and assessed the FXIa inhibitory potency of a series of 5-phenyl-1H-pyrazole-3-carboxamide derivatives with different P1, P1′ and P2′moiety. Finally, the SAR of them was systematically investigated to afford the lead compound 7za (FXIa Ki = 90.37 nM, 1.5× aPTT in rabbit plasma = 43.33μM) which exhibited good in vitro inhibitory potency against FXIa and excellent in vitro coagulation activities. Furthermore, the binding mode of 7za with FXIa was studied and the results suggest that the 2-methylcyclopropanecarboxamide group of 7za makes 2 direct hydrogen bonds with Tyr58B and Thr35 in the FXIa backbone, making 7za binds to FXIa in a highly efficient manner.

  FXIa被认为是抗凝药物发现的主要靶点，因为减少了出血风险。在这篇论文中，我们将5-苯基-1H-吡唑-3-羧酸衍生物定义为FXIa抑制剂的引物片段，用于引物发现。在将化合物3中的(E)-3-(5-氯-2-(1H-四唑-1-基)苯基)丙烯酰胺基团替换为5-(3-氯苯基)-1H-吡唑-3-羧酰胺后，我们从FXIa抑制剂3转变为将引物片段融合成FXIa抑制剂的药效团的支架。随后，我们合成并评估了一系列具有不同P1、P1'和P2'基团的5-苯基-1H-吡唑-3-羧酰胺衍生物的FXIa抑制活性。最后，对它们的结构活性关系进行了系统研究，得到了引物化合物7za（FXIa Ki = 90.37 nM，在兔血浆中1.5× aPTT = 43.33μM），该化合物表现出良好的体外抑制FXIa活性和优秀的体外凝血活性。此外，研究了7za与FXIa的结合方式，结果表明7za的2-甲基环丙烷甲酰胺基团与FXIa骨架中的Tyr58B和Thr35直接形成两个氢键，使7za以高效的方式结合到FXIa上。
• Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators
  作者：Eunhee Chae、Yong-Je Shin、Eun-Ju Ryu、Mi Kyung Ji、Nahm Ryune Cho、Ki-Ho Lee、Hyun Ji Jeong、Soo-Jin Kim、Yeonjung Choi、Kyung Seok Oh、Chun-Eung Park、Young Soo Yoon

  DOI：10.1016/j.bmcl.2013.01.116

  日期：2013.4

  Development of SAR in a 5-aryl-3-acylpyridinyl-pyrazoles and 1-aryl-4-acylpyridinyl imidazoles series of mGlu5 receptor negative allosteric modulators (mGluR5 NAMs) using a functional cell-based assay is described in this Letter. Analysis of the Ligand-lipophilic efficiency (LipE) of compounds provided new insight for the design of potent mGluR5 negative allosteric modulators with anti-depressant activities. (C) 2013 Elsevier Ltd. All rights reserved.